Drug Profile
Barusiban - Ferring Pharmaceuticals
Alternative Names: FE 200 440Latest Information Update: 15 Apr 2021
Price :
$50
*
At a glance
- Originator Ferring Pharmaceuticals
- Class Infertility therapies; Oligopeptides; Tocolytics
- Mechanism of Action Oxytocin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Female infertility
- Discontinued Preterm labour
Most Recent Events
- 15 Apr 2021 No development reported - Phase-II for Female infertility in Czech Republic, Canada, Australia, Poland, Spain, Belgium (SC) (Ferring Pharmaceuticals' pipeline, April 2021)
- 15 Jan 2018 Barusiban is still at phase II development stage for Female infertility in Australia, Belgium, Canada, Czech Republic, Poland and Spain (SC)
- 15 Jan 2018 Discontinued - Phase-II for Preterm labour (Prevention) in Finland, Lithuania, Poland, Romania, Czech Republic, Belgium (IV) (Indication not listed on Ferring pipeline, January 2018)